The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...
Hosted on MSN7mon
Roche Jumps After Weight-Loss Pill Shows Promise in Study(Bloomberg) -- Roche Holding AG shares jumped after its experimental weight loss pill showed meaningful weight reduction in an early stage study among obesity patients, setting up the Swiss ...
Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...
A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...
Hosted on MSN6mon
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming MarketRoche Holding AG (OTC:RHHBY) reportedly turned down a potential blockbuster weight-loss pill in 2018, allowing Eli Lilly And Co (NYSE:LLY) to acquire the drug, now known as orforglipron ...
In an interview with pharmaphorum, Marius Scholtz, country medical lead for Roche UK, said the drug will have around the same yearly cost in relapsing disease as Novartis’ once-daily pill ...
Roche has reported early-stage clinical data ... The new results are from a phase 1 trial of a once-daily pill called CT-966, which revealed an average weight loss of 7.3% at four weeks in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback